Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This study is aimed to determine the maximum tolerated dose of ensartinib, an oral ALK
inhibitor in Chinese patients with ALK-positive non-small cell lung cancer